Drug Pricing
Our work in Drug Pricing
-
Limitations of Traditional Health Technology Assessment Methods and Implications for the Evaluation of Innovative Therapies
Jason Doctor and Joanna MacEwan provide guidance for addressing emerging challenges and new methods of health technology assessments.
Categorized in -
The Cost of Adherence Mismeasurement in Serious Mental Illness: A Claims-Based Analysis
This study demonstrates that common pharmacy claims-based measures underestimate the effect of actual adherence on inpatient costs among patients with serious mental illness.
Categorized in -
The Total Direct Cost of Healthcare in the United States in Patients with Crohn’s Disease and Ulcerative Colitis: An Age Specific Analysis
This study evaluated the total direct costs calculated from medical services and outpatient pharmacy costs and the annual incremental health care cost burden in the years after diagnosis of Crohn’s disease and ulcerative colitis.
Categorized in -
Innovative Contracting for Pharmaceuticals and Medicaid’s Best-Price Rule
This paper examines Medicaid’s “best-price rule” and assesses to what extent, if any, it might frustrate the goal of paying for value.
Categorized in -
Value-Based Pricing For Pharmaceuticals In The Trump Administration
The change in administration is an opportune moment for CMS to assume a leadership role with respect to value-based pricing.
Categorized in -
A Good Deal For Eliminating Hepatitis C: Saving Money And Lives
Hepatitis C kills more than 20,000 Americans each year. A recent consensus committee of the National Academies of Sciences, Engineering, and Medicine proposed a novel strategy to improve access to hepatitis C medicines.
Categorized in -
Schaeffer Center Panel Divides Over Prospect of Medicare Drug Price Negotiation
The debate is increasingly focused on the tradeoff between innovation and access.
-
What Role Should Government Play in Drug Price Negotiations?
President Trump and Democrat lawmakers are discussing allowing Medicare to negotiate drug prices directly with manufacturers, and the idea is popular with voters. While it seems intuitive that negotiations should lead to lower drug costs, the truth is far less clear. The nonpartisan Congressional Budget Office has predicted that negotiations will lead to minimal savings, […]
Categorized in -
Sky-High Drug Prices for Rare Diseases Show Why Orphan Drug Act Needs Reform
The Orphan Drug Act (ODA) was passed 34 years ago to promote development of drugs aimed at diseases that afflict small groups, typically under 200,000 people. However, the nature of drug development has changed. Our researchers see an opportunity for improvement.
Categorized in -
The Value of a Cure: Ensuring Access and Encouraging Innovation
Innovations in medical research and technology have produced cures and breakthrough therapies to overcome diseases that were once considered a death sentence. But are these breakthroughs reaching all communities? How can we balance the high costs of drug development with affordability? And what can we do to ensure that new cures continue to be developed?
Categorized in